PT1425005E - Composicao farmaceutica que compreende lumiracoxib - Google Patents

Composicao farmaceutica que compreende lumiracoxib

Info

Publication number
PT1425005E
PT1425005E PT02767455T PT02767455T PT1425005E PT 1425005 E PT1425005 E PT 1425005E PT 02767455 T PT02767455 T PT 02767455T PT 02767455 T PT02767455 T PT 02767455T PT 1425005 E PT1425005 E PT 1425005E
Authority
PT
Portugal
Prior art keywords
tablets
lumiracoxib
understands
pharmaceutical composition
administration
Prior art date
Application number
PT02767455T
Other languages
English (en)
Inventor
Karnachi Anees Abdulquadar
Bateman Simon David
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT1425005E publication Critical patent/PT1425005E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT02767455T 2001-08-31 2002-08-30 Composicao farmaceutica que compreende lumiracoxib PT1425005E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31638901P 2001-08-31 2001-08-31

Publications (1)

Publication Number Publication Date
PT1425005E true PT1425005E (pt) 2006-09-29

Family

ID=23228840

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02767455T PT1425005E (pt) 2001-08-31 2002-08-30 Composicao farmaceutica que compreende lumiracoxib

Country Status (30)

Country Link
US (2) US20030114527A1 (pt)
EP (1) EP1425005B1 (pt)
JP (1) JP4636796B2 (pt)
KR (1) KR100895551B1 (pt)
CN (1) CN100406008C (pt)
AR (1) AR036312A1 (pt)
AT (1) ATE324883T1 (pt)
AU (1) AU2002331094B2 (pt)
BR (1) BR0212155A (pt)
CA (1) CA2456604C (pt)
CO (1) CO5560554A2 (pt)
CY (1) CY1106137T1 (pt)
DE (1) DE60211183T2 (pt)
DK (1) DK1425005T3 (pt)
EC (1) ECSP044986A (pt)
ES (1) ES2263813T3 (pt)
HK (1) HK1087336A1 (pt)
HU (1) HUP0401429A2 (pt)
IL (1) IL160375A0 (pt)
MX (1) MXPA04001933A (pt)
MY (1) MY137516A (pt)
NO (1) NO20040860L (pt)
NZ (1) NZ531342A (pt)
PE (1) PE20030323A1 (pt)
PL (1) PL367464A1 (pt)
PT (1) PT1425005E (pt)
RU (1) RU2329801C2 (pt)
SI (1) SI1425005T1 (pt)
WO (1) WO2003020261A1 (pt)
ZA (1) ZA200400877B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020351A1 (es) * 2000-09-11 2002-06-14 Novartis Ag Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
GB0201520D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Pharmaceutical uses
RU2318497C2 (ru) * 2002-03-07 2008-03-10 Новартис Аг Фармацевтические композиции
US8148414B2 (en) 2008-08-19 2012-04-03 Xenoport, Inc. Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
US20140093563A1 (en) * 2011-06-13 2014-04-03 Ranbaxy Laboratories Limited Febuxostat compositions
US10952968B2 (en) 2012-05-14 2021-03-23 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
US9597292B2 (en) 2012-08-22 2017-03-21 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
EP2887934A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
EA018867B1 (ru) * 2012-11-01 2013-11-29 Лаборатория Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции и продукт способа
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
JP2016534133A (ja) 2013-09-06 2016-11-04 ゼノポート，インコーポレイティド （ｎ，ｎ−ジエチルカルバモイル）メチル メチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用
BR112016015944A8 (pt) * 2014-01-10 2020-06-09 Johnson & Johnson Consumer Inc processo para produzir comprimido, que usa radiofrequência e partículas revestidas dissipadoras de energia
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028936A1 (en) * 1993-06-08 1994-12-22 Ciba-Geigy Ag Process for the preparation of an oral solid dosage form containing diclofenac
CN1140267C (zh) * 1996-05-17 2004-03-03 麦克公司 治疗环加氧酶-2介导的疾病的每天一次的组合物
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
PE20020351A1 (es) * 2000-09-11 2002-06-14 Novartis Ag Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2

Also Published As

Publication number Publication date
KR100895551B1 (ko) 2009-04-29
IL160375A0 (en) 2004-07-25
EP1425005B1 (en) 2006-05-03
DE60211183T2 (de) 2007-02-01
WO2003020261A1 (en) 2003-03-13
NZ531342A (en) 2005-09-30
CA2456604A1 (en) 2003-03-13
DE60211183D1 (de) 2006-06-08
ES2263813T3 (es) 2006-12-16
CO5560554A2 (es) 2005-09-30
EP1425005A1 (en) 2004-06-09
SI1425005T1 (sl) 2006-12-31
RU2329801C2 (ru) 2008-07-27
HUP0401429A2 (hu) 2004-11-29
CY1106137T1 (el) 2011-06-08
AR036312A1 (es) 2004-08-25
PE20030323A1 (es) 2003-05-12
MY137516A (en) 2009-02-27
CN1728993A (zh) 2006-02-01
NO20040860L (no) 2004-04-22
DK1425005T3 (da) 2006-09-04
CA2456604C (en) 2011-02-08
CN100406008C (zh) 2008-07-30
HK1087336A1 (en) 2006-10-13
AU2002331094B2 (en) 2006-08-31
MXPA04001933A (es) 2004-06-15
PL367464A1 (en) 2005-02-21
JP4636796B2 (ja) 2011-02-23
BR0212155A (pt) 2004-07-13
RU2004109920A (ru) 2005-04-20
ZA200400877B (en) 2004-11-01
US20070231382A1 (en) 2007-10-04
JP2005520785A (ja) 2005-07-14
ATE324883T1 (de) 2006-06-15
ECSP044986A (es) 2004-04-28
KR20040031019A (ko) 2004-04-09
US20030114527A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
HK1087336A1 (en) Pharmaceutical composition comprising lumiracoxib
IL186655A0 (en) Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical formulations
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
BR9917012A (pt) Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
IS7006A (is) Tvívetnis 3-piperidínóprópíófenon og lyf sem innihalda téð efnasambönd
BG105173A (en) Novel salt form of pantoprazole
DE602008006243D1 (de) Pharmazeutische kombination aus aliskiren und valsartan
CA2416771A1 (en) 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid for treatment of cox-2 dependent disorders
MXPA05008843A (es) Sistema terapeutico que comprende amoxicilina y acido clavulanico.
GEP20043377B (en) Pharmaceutical Complex
HK1075654A1 (en) Hyperforin derivatives, the use thereof and formulations containing them
PT1490049E (pt) Citalopram para o tratamento da pre3ssao sanguinia elevada.
RU2003117877A (ru) Фармацевтическая композиция для лечения воспалительных процессов вирусной этиологии в глазном яблоке
HUP0200148A2 (hu) N-(3',4'-dimetoxi-cinnamoil)antranilsav alkalmazása szívkoszorúér-műtéttel kapcsolatos cardiovascularis események megelőzésére vagy mérséklésére
TH65639A (th) องค์ประกอบทางเภสัชกรรม
BRPI0415111A (pt) composição farmacêutica que compreende o ácido 5-metil-2-( 2`-cloro-6`-fluoroanilino) fenilacético
UY26605A1 (es) Sistema de administración oral controlada para la ingestión diaria de ciprofloxacina
CY1110563T1 (el) Παραγωγο του ισοξαζολικου οξεος για την ανακουφιση νευροπαθητικου πονου